Summary
Signal counts
Assets tracked: 6
Watchlist assets: 4
Registry stop assets: 0
Sponsor overview
Shanghai Zhongshan Hospital
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT05994001 | https://clinicaltrials.gov/study/NCT07570849 | https://clinicaltrials.gov/study/NCT06587425 | https://clinicaltrials.gov/study/NCT06654830 | https://clinicaltrials.gov/study/NCT05143099 | https://clinicaltrials.gov/study/NCT05190575 | https://clinicaltrials.gov/study/NCT04396821
Assets
Linked programs
- cardonilizumab: Low Signal (0/5)
- Chidamide, Gemcitabine, cisplatin, immune checkpoint inhibitor: Low Signal (1/5)
- LM-302+Candonilimab+Capecitabine: Timeline Staleness Signal (2/5)
- RATT: Watchlist Signal (2/5)
- TEC: Timeline Staleness Signal (4/5)
- TST001: Results Not Found Signal (2/5)